Etopride50 mg

Etopride is a prokinetic agent used for the symptomatic treatment of gastrointestinal motility disorders. Its indications, classified by strength of evidence, are as follows:

Established / Guideline-Supported Use

• Functional (non-ulcer) dyspepsia: Etopride is indicated for relief of the gastrointestinal symptoms associated with functional dyspepsia, including upper abdominal bloating, early satiety, postprandial fullness, upper abdominal discomfort or pain, nausea, and vomiting, in patients where organic disease (e.g. peptic ulcer, malignancy) has been excluded.

Adjunct / Supportive Use

• Etopride is sometimes used as an adjunct to standard care for mild gastroparesis-type symptoms (delayed gastric emptying with fullness, bloating, and early satiety), typically alongside dietary measures and treatment of any underlying cause.

Etopride is not indicated for structural or mechanical causes of gastrointestinal symptoms, which require separate diagnostic evaluation and management.

Each film-coated tablet commonly available in Bangladesh contains Itopride Hydrochloride INN 50 mg. Dispersible tablet and sustained-release formulations of Itopride Hydrochloride are also marketed in some regions; strength and formulation should be confirmed on the specific product label before dispensing.

Etopride is a gastroprokinetic agent that enhances upper gastrointestinal motility. It works through a dual mechanism — antagonism of dopamine D2 receptors and inhibition of acetylcholinesterase — which together increase local acetylcholine activity in the gut wall, strengthen gastric antral contractions, coordinate gastroduodenal motility, and accelerate gastric emptying.

Unlike some older prokinetic agents, Etopride penetrates the blood-brain barrier only to a limited extent, which is associated with a lower incidence of central dopaminergic (extrapyramidal) side effects. It is used primarily for the relief of symptoms of functional dyspepsia.

Etopride belongs to the therapeutic class of Prokinetic agents (Gastro-prokinetics), specifically classified as a dopamine D2-receptor antagonist with acetylcholinesterase-inhibiting activity, used in the management of upper gastrointestinal motility disorders.

Mechanism of Action

Itopride Hydrochloride acts as a selective dopamine D2-receptor antagonist and, concurrently, as an acetylcholinesterase inhibitor. Blockade of presynaptic and postsynaptic D2 receptors in the gut increases acetylcholine release, while acetylcholinesterase inhibition reduces its breakdown; the combined effect is enhanced, coordinated cholinergic stimulation of gastrointestinal smooth muscle. This increases lower esophageal sphincter pressure, strengthens gastric antral contractions, improves gastroduodenal coordination, and accelerates gastric emptying. Itopride Hydrochloride also has mild central antiemetic activity via D2 antagonism in the chemoreceptor trigger zone.

Pharmacokinetics

• Absorption: Rapidly and almost completely absorbed after oral administration; peak plasma concentration is typically reached within about 30–45 minutes.
• Metabolism: Metabolized predominantly by flavin-containing monooxygenase (FMO3) to an N-oxide metabolite, with only minor involvement of cytochrome P450 enzymes — this gives Itopride Hydrochloride a comparatively low potential for CYP-mediated drug interactions relative to some other prokinetic agents.
• Elimination half-life: Approximately 6 hours.
• Excretion: Predominantly renal, mainly as metabolites.

Clinical studies have not shown clinically significant QT-interval prolongation with Itopride Hydrochloride at recommended doses, distinguishing it from some other prokinetic agents that carry cardiac conduction warnings.

Etopride tablets should be taken orally, generally before meals, swallowed whole with a glass of water. Dispersible tablets, where available, should be dispersed in water as directed on the product label before administration. Do not exceed the prescribed dose or frequency.

Etopride undergoes minimal cytochrome P450-mediated metabolism (it is metabolized mainly by flavin-containing monooxygenase), giving it a comparatively favorable drug-interaction profile relative to some other prokinetic agents. Clinically relevant interactions include:

• Anticholinergic drugs (e.g. atropine, other antimuscarinics): may antagonize the prokinetic effect of Etopride through opposing cholinergic mechanisms; concurrent use should be avoided or undertaken with awareness of reduced efficacy.
• Drugs whose absorption depends on gastrointestinal transit time: because Etopride accelerates gastric emptying, the rate (and occasionally extent) of absorption of concurrently administered oral medications may be altered; timing of administration should be considered for narrow-therapeutic-index drugs.
• H2-receptor antagonists and proton pump inhibitors (e.g. cimetidine, omeprazole): no clinically significant pharmacokinetic interaction has been established; Etopride is commonly co-prescribed with acid-suppressing agents in dyspepsia management.

Etopride is generally well tolerated. Reported adverse effects include:

Because Etopride has limited penetration across the blood-brain barrier, central dopaminergic effects (extrapyramidal symptoms) are reported less often than with some other dopamine-antagonist prokinetic agents, though they cannot be entirely excluded.

Pregnancy: Data on the use of Etopride in pregnant women are limited. Etopride should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether Etopride is excreted in human breast milk. Caution is advised, and a physician should be consulted before using Etopride while breastfeeding, weighing the benefit of therapy against potential risk to the infant.

• Etopride should not be used in confirmed gastrointestinal obstruction, perforation, or hemorrhage (see Contraindications).
• Use with caution in patients with significant renal or hepatic impairment, as clearance of Etopride may be reduced; clinical monitoring is advised.
• Use with caution in elderly patients, who may have reduced renal function.
• Monitor for signs of hyperprolactinemia (e.g. galactorrhea, menstrual irregularity, gynecomastia) with prolonged use.
• If symptoms do not improve within the expected treatment course, reassess the diagnosis rather than continuing Etopride empirically.

Limited clinical experience with overdosage of Etopride is available. Based on its pharmacology, an overdose may be expected to exaggerate known adverse effects (e.g. gastrointestinal upset, headache). There is no specific antidote for Etopride overdose.

In case of suspected overdose, seek immediate medical attention or contact emergency services / a poison control center. Management should be supportive and symptomatic, with monitoring of vital signs as clinically indicated; gastric decontamination and other supportive measures should be undertaken only under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Use Etopride with caution in patients with significant renal impairment; no formal dose-adjustment schedule is well established, so clinical monitoring is advised (see Precautions and Warnings).

Hepatic Impairment

Use Etopride with caution in patients with significant hepatic impairment, with clinical monitoring for adverse effects.

Elderly

No specific dose reduction is generally required, but elderly patients should be monitored closely given the possibility of age-related decline in renal function.

Pediatric Population

Safety and efficacy of Etopride have not been well established in children; use is generally not recommended outside specialist guidance (see Pediatric Use).

Pregnancy and Lactation

See Pregnancy and Lactation section for detailed guidance.

Etopride is typically prescribed for a limited course of 2 to 8 weeks for functional dyspepsia, depending on symptom response. If symptoms persist beyond this period or worsen, the patient should be reassessed by a physician, and continued use should be guided by clinical response rather than fixed duration.

Itopride Hydrochloride is classified under: Prokinetic agents; Gastrointestinal motility stimulants; Dopamine D2-receptor antagonists with acetylcholinesterase-inhibitory activity.

Itopride Hydrochloride exerts its prokinetic effect through dual dopamine D2-receptor antagonism and acetylcholinesterase inhibition, which together increase acetylcholine activity at the gastrointestinal smooth muscle, enhance antral contractility, and accelerate gastric emptying (see Pharmacology for full detail).

The safety and efficacy of Etopride in pediatric patients have not been well established through adequate controlled studies. Use in children is generally not recommended outside specialist advice, and if considered necessary, should only be undertaken under close medical supervision with careful weighing of potential benefits against unknown risks.